Skip to main content
Clinical Trials/NCT00264225
NCT00264225
Completed
Phase 3

A Randomized, Double-Blind, Comparative Parallel Group Study of Analgesic Effectiveness and Safety of Three Different Doses of Lamaline® New Formulation vs Dafalgan® Codeine, After 10 Days Administration in Subjects With Painful Gonarthrosis.

Solvay Pharmaceuticals171 sites in 1 countryStarted: December 2005Last updated:

Overview

Phase
Phase 3
Status
Completed
Locations
171

Overview

Brief Summary

This study aims to assess the analgesic effectiveness and safety of three different doses of a new formulation of Lamaline® versus Dafalgan® Codeine after 10 days administration in subjects with painful gonarthrosis

Study Design

Study Type
Interventional
Allocation
Randomized
Intervention Model
Parallel
Primary Purpose
Treatment
Masking
Double

Eligibility Criteria

Ages
40 Years to 85 Years (Adult, Older Adult)
Sex
All
Accepts Healthy Volunteers
No

Inclusion Criteria

  • History of knee (unilateral or bilateral) osteoarthritis for at least 6 months
  • Pain intensity assessed by Visual Analogue Scale ≥ 40 mm
  • Partial functional disability assessed by Lequesne index ≥4 and \< than 12

Exclusion Criteria

  • Patient unable to interrupt his/her NSAIDs to participate in the clinical study

Investigators

Sponsor Class
Industry

Study Sites (171)

Loading locations...

Similar Trials